5-hydroxy-L-tryptophan

EEG alterations following exogenous 5-HT/5-HTP administration

Successful acupuncture produces EEG-alterations especially in younger patients as seen after exogene administration of 5-HT respectively 5-HTP i.v.

PMID:1085345 · one of two readings recorded this

EEG alterations following exogenous administration of 5-HT and 5-HTP

Successful acupuncture produces EEG-alterations especially in younger patients as seen after exogene administration of 5-HT respectively 5-HTP i.v.

PMID:1085345 · one of two readings recorded this

frequency of occurrence and amplitude of intention myoclonus

decreases, decreased the frequency of occurrence and amplitude of intention myoclonus in two patients with posthypoxic intention myoclonus and in one with idiopathic myoclonus, n = 3

This treatment (1) decreased the frequency of occurrence and amplitude of intention myoclonus in two patients with posthypoxic intention myoclonus and in one with idiopathic myoclonus.

PMID:1086988 · both readings recorded this

frequency of occurrence and amplitude of myoclonus

increases, increased the frequency of occurrence and amplitude of myoclonus in two patients with lipid storage disease, one with myoclonic epilepsy, and one additional patient with idiopathic myoclonus, n = 4

This treatment (3) increased the frequency of occurrence and amplitude of myoclonus in two patients with lipid storage disease, one with myoclonic epilepsy, and in an additional patient with idiopathic myoclonus.

PMID:1086988 · one of two readings recorded this

depression alleviation, pooled odds ratio combining a 5-HT and a tryptophan study

increases, Peto OR = 4.1, 95% CI = 1.3-13.2, n = 64

These studies suggest 5-HT and L-tryptophan are better than placebo at alleviating depression (Peto OR = 4.1, 95% CI = 1.3-13.2).

PMID:12169147 · one of two readings recorded this

depression response to serotonergic precursor treatment (pooled odds ratio)

increases, Peto OR = 4.1, 95% CI = 1.3-13.2, n = 64

Not recorded as a finding: the supporting sentence never names the compound

These studies suggest 5-HT and L-tryptophan are better than placebo at alleviating depression (Peto OR = 4.1, 95% CI = 1.3-13.2).

PMID:12169147 · one of two readings recorded this

Body weight loss, first 6-wk period without diet

decreases, n = 20

Significant weight loss was observed in 5-HTP-treated patients during both periods

PMID:1384305 · one of two readings recorded this

Body weight loss, second 6-wk period with diet

decreases, n = 20

Significant weight loss was observed in 5-HTP-treated patients during both periods

PMID:1384305 · one of two readings recorded this

Carbohydrate intake

decreases, n = 20

A reduction in carbohydrate intake and a consistent presence of early satiety were also found

PMID:1384305 · one of two readings recorded this

Early satiety

increases, n = 20

A reduction in carbohydrate intake and a consistent presence of early satiety were also found

PMID:1384305 · one of two readings recorded this

weight loss in obese patients on oral 5-HTP 900 mg/d versus placebo, over two 6-week periods

decreases, significant weight loss in 5-HTP-treated patients during both periods, n = 20

Not recorded as a finding: the result compares a group with itself, not with a control

Significant weight loss was observed in 5-HTP-treated patients during both periods.

PMID:1384305 · one of two readings recorded this

weight loss in obese patients over two 6-week periods; carbohydrate intake; early satiety

decreases, significant weight loss in 5-HTP-treated patients in both periods

Not recorded as a finding: the result compares a group with itself, not with a control

Significant weight loss was observed in 5-HTP-treated patients during both periods.

PMID:1384305 · one of two readings recorded this

Maintenance of abstinence by treatment condition

no effect, n = 31

there was no significant effect of the treatment condition on maintenance of abstinence

PMID:1424429 · one of two readings recorded this

Maintenance of abstinence from alcohol for 1 year (all patients entering analysis)

n = 31

Eight of 31 patients who entered the analysis remained abstinent from alcohol for 1 year

PMID:1424429 · one of two readings recorded this

maintenance of abstinence from alcohol over 1 year in patients with alcoholism

no effect, no significant effect of the treatment condition on maintenance of abstinence, n = 31

Not recorded as a finding: the intervention held more than the compound

Eight of 31 patients who entered the analysis remained abstinent from alcohol for 1 year; however, there was no significant effect of the treatment condition on maintenance of abstinence.

PMID:1424429 · one of two readings recorded this

maintenance of abstinence from alcohol over 1 year

no effect

Not recorded as a finding: this platform holds no node for the endpoint

Eight of 31 patients who entered the analysis remained abstinent from alcohol for 1 year; however, there was no significant effect of the treatment condition on maintenance of abstinence.

PMID:1424429 · one of two readings recorded this

occurrence of toxicity/adverse events with 5-HTP dietary supplement use

no effect

However, no definitive cases of toxicity have emerged despite the worldwide usage of 5-HTP for last 20 years, with the possible exception of one unresolved case of a Canadian woman.

PMID:15068828 · one of two readings recorded this

presence of toxic contaminants in commercial 5-HTP preparations

no effect

Extensive analyses of several sources of 5-HTP have shown no toxic contaminants similar to those associated with L-Trp, nor the presence of any other significant impurities.

PMID:15068828 · one of two readings recorded this

melanin formation from 5-hydroxytryptophan oxidative polymerization

increases

We observed that both enzymes converted this substrate to melanin and that peroxidase, in the presence of hydrogen peroxide, was much more effective than tyrosinase in catalysing the oxidative polymerization of 5-hydroxytryptophan, with the formation of insoluble black melanin-like pigments.

PMID:15206795 · one of two readings recorded this

melanin pigment formation from 5-hydroxytryptophan oxidation

increases

We observed that both enzymes converted this substrate to melanin and that peroxidase, in the presence of hydrogen peroxide, was much more effective than tyrosinase in catalysing the oxidative polymerization of 5-hydroxytryptophan, with the formation of insoluble black melanin-like pigments.

PMID:15206795 · one of two readings recorded this

24-hour urinary 5-HIAA excretion

increases, 204 micromol/day vs 18 micromol/day, p = 0.017

Median (range) urinary 5-HIAA excretion was 204 micromol/day (22 micromol/day to 459 micromol/day) during 5-HTP intake, compared with 18 micromol/day (12 micromol/day to 36 micromol/day) during placebo intake (P=0.017).

PMID:18209781 · one of two readings recorded this

serum chromogranin A concentration

no effect

Not recorded as a finding: no matching outcome node for serum chromogranin A

5-HTP did not affect clinical symptoms or serum CgA levels.

PMID:18209781 · one of two readings recorded this

serum chromogranin A

no effect

5-HTP did not affect clinical symptoms or serum CgA levels.

PMID:18209781 · one of two readings recorded this

hot flash frequency, electronic humidity-based recorder

no effect

There were no significant effects whatsoever from the analysis of hot flash frequencies (Table 2).

PMID:20031347 · one of two readings recorded this

hot flash frequency (episodes per 24 hours) by electronic humidity-based recorder

no effect

Not recorded as a finding: this platform holds no node for the endpoint

There were no significant effects whatsoever from the analysis of hot flash frequencies (Table 2).

PMID:20031347 · one of two readings recorded this

All clinical parameters studied (fibromyalgia)

increases, n = 50

All the clinical parameters studied were significantly improved by treatment with 5-HTP and only mild and transient side-effects were reported

PMID:2193835 · one of two readings recorded this

clinical parameters of primary fibromyalgia syndrome (unnamed in abstract)

increases, all clinical parameters significantly improved, no figures

Not recorded as a finding: no estimate is reported anywhere

All the clinical parameters studied were significantly improved by treatment with 5-HTP and only mild and transient side-effects were reported.

PMID:2193835 · one of two readings recorded this

unnamed clinical parameters of primary fibromyalgia syndrome, 5-HTP versus placebo; no instrument named in the abstract

increases, all clinical parameters studied significantly improved, n = 50

Not recorded as a finding: this platform holds no node for the endpoint

All the clinical parameters studied were significantly improved by treatment with 5-HTP and only mild and transient side-effects were reported.

PMID:2193835 · one of two readings recorded this

REM sleep fragmentation and baseline REM efficiency in abstinent alcoholics given oral 5-HTP loading

decreases, decreased fragmentation was found in the majority of subjects, with more improvement in those with lower baseline REM efficiency

Not recorded as a finding: this platform holds no node for the endpoint

Decreased fragmentation was found in the majority of subjects, and those subjects with low baseline REM efficiency (i.e., greater fragmentation) showed more improvement from the drug than did subjects who were less impaired initially.

PMID:233794 · one of two readings recorded this

REM sleep fragmentation and baseline REM efficiency

decreases, decreased fragmentation was found in the majority of subjects, and those with low baseline REM efficiency showed more improvement from the drug than those less impaired initially

Decreased fragmentation was found in the majority of subjects, and those subjects with low baseline REM efficiency (i.e., greater fragmentation) showed more improvement from the drug than did subjects who were less impaired initially.

PMID:233794 · one of two readings recorded this

REM sleep fragmentation (REM efficiency)

decreases, decreased fragmentation in the majority of subjects; greater improvement in subjects with lower baseline REM efficiency

Not recorded as a finding: this platform holds no node for the endpoint

Decreased fragmentation was found in the majority of subjects, and those subjects with low baseline REM efficiency (i.e., greater fragmentation) showed more improvement from the drug than did subjects who were less impaired initially.

PMID:233794 · one of two readings recorded this

Plasma aldosterone

no effect

mean (SD) aldosterone (ng/dl) at 8 h after dosing was 12.0 +/- 5.1 and 12.0 +/- 3.8 after placebo (NS)

PMID:2474017 · one of two readings recorded this

serum prolactin concentration and plasma and urinary aldosterone after oral L-5-HTP 100 mg qid with carbidopa 50 mg qid versus matching placebos, on background dexamethasone

increases, prolactin at 8 h 19.8 +/- 6.3 ng/ml after L5HTP/C versus 12.0 +/- 3.1 after placebo; aldosterone not different, n = 8

Not recorded as a finding: this platform holds no node for the endpoint

Serum prolactin concentration increased in all subjects after L5HTP/C in comparison to placebo, mean (SD) prolactin (ng/ml) at 8 h after dosing was 19.8 +/- 6.3 after L5HTP/C and 12.0 +/- 3.1 after placebo (p less than 0.05).

PMID:2474017 · one of two readings recorded this

serum prolactin; plasma and urinary aldosterone after repeated oral doses

increases, prolactin at 8 h 19.8 +/- 6.3 after L5HTP/C vs 12.0 +/- 3.1 after placebo

Not recorded as a finding: the intervention held more than the compound

Serum prolactin concentration increased in all subjects after L5HTP/C in comparison to placebo, mean (SD) prolactin (ng/ml) at 8 h after dosing was 19.8 +/- 6.3 after L5HTP/C and 12.0 +/- 3.1 after placebo (p less than 0.05).

PMID:2474017 · one of two readings recorded this

Serum prolactin

increases, p = 0.05

mean (SD) prolactin (ng/ml) at 8 h after dosing was 19.8 +/- 6.3 after L5HTP/C and 12.0 +/- 3.1 after placebo (p less than 0.05)

PMID:2474017 · one of two readings recorded this

Urinary aldosterone excretion

no effect

7.0 +/- 4.4, 49.3 +/- 30.6, 30.1 +/- 11.2, after L5HTP/C and 7.4 +/- 5.8, 59.7 +/- 23.9, 33.3 +/- 7.4 after placebo (NS)

PMID:2474017 · one of two readings recorded this

Urinary potassium excretion

no effect

7.0 +/- 4.4, 49.3 +/- 30.6, 30.1 +/- 11.2, after L5HTP/C and 7.4 +/- 5.8, 59.7 +/- 23.9, 33.3 +/- 7.4 after placebo (NS)

PMID:2474017 · one of two readings recorded this

Urinary sodium excretion

no effect

7.0 +/- 4.4, 49.3 +/- 30.6, 30.1 +/- 11.2, after L5HTP/C and 7.4 +/- 5.8, 59.7 +/- 23.9, 33.3 +/- 7.4 after placebo (NS)

PMID:2474017 · one of two readings recorded this

5-HT3R and 5-HT5R expression in colonic mucosa

increases

the plasma 5-HT levels, 5-HIAA concentrations, TPH1 expression in the colonic mucosa, and 5-HT3R and 5-HT5R expression were increased in both the IBS-D and the UC remission groups

PMID:27022227 · one of two readings recorded this

5-HT7R expression in colonic mucosa

no effect

no increases were observed with respect to 5-HT7R expression

PMID:27022227 · one of two readings recorded this

Anorectal relaxation pressure

increases

these groups exhibited significantly increased anorectal relaxation pressure

PMID:27022227 · one of two readings recorded this

Initial perception, defecating and pain thresholds (rectal visceral sensitivity)

decreases

the UC remission and IBS-D groups showed a decrease in the initial perception threshold, defecating threshold and pain threshold

PMID:27022227 · one of two readings recorded this

Pain threshold and colonic 5-HT7R expression, IBS-D versus UC remission

modulates

However, the pain threshold and 5-HT7R expression in the colonic mucosa were significantly different between these groups

PMID:27022227 · one of two readings recorded this

Plasma 5-HIAA concentration

increases

the plasma 5-HT levels, 5-HIAA concentrations, TPH1 expression in the colonic mucosa, and 5-HT3R and 5-HT5R expression were increased in both the IBS-D and the UC remission groups

PMID:27022227 · one of two readings recorded this

Plasma 5-HT level

increases

the plasma 5-HT levels, 5-HIAA concentrations, TPH1 expression in the colonic mucosa, and 5-HT3R and 5-HT5R expression were increased in both the IBS-D and the UC remission groups

PMID:27022227 · one of two readings recorded this

TPH1 expression in colonic mucosa

increases

the plasma 5-HT levels, 5-HIAA concentrations, TPH1 expression in the colonic mucosa, and 5-HT3R and 5-HT5R expression were increased in both the IBS-D and the UC remission groups

PMID:27022227 · one of two readings recorded this

brain 5-HTExt elevation beyond SSRI monotherapy effect in mice

increases

Adjunctive 5-HTP SR augmented the 5-HTExt-elevation induced by chronic SSRI, by 100 % in wildtype mice and by 800 % in mice with naturalistic 5-HT deficiency, respectively.

PMID:27692695 · one of two readings recorded this

cortisol rise as a peripheral biomarker of brain extracellular serotonin (5-HTExt) elevation

increases

Similarly, in human healthy volunteers, Lowe et al. found that oral 200 mg 5-HTP or an SSRI elevated cortisol by 35 % and 100 %, respectively.

PMID:27692695 · one of two readings recorded this

central and enteric neuron serotonin (5-HT) levels

increases

Administration of 5-HTP SR to adult TPH2-R439H mice restored 5-HT to enteric neurons and reversed these abnormalities.

PMID:31071306 · one of two readings recorded this

colonic migrating motor complex (CMMC) measures and enteric epithelial growth

increases

Intestinal tissue from these mice had normal measures of CMMCs and enteric epithelial growth

PMID:31071306 · one of two readings recorded this

depressive-like behaviors in TPH2-R439H mice

decreases

Not recorded as a finding: no outcome node for rodent depressive-like-behaviour assays

Feeding chow that contains 5-HTP slow release (5-HTP SR) to TPH2-R439H mice restores levels of 5-HT in the central nervous system and reduces depressive-like behaviors.

PMID:31071306 · one of two readings recorded this

depressive-like behaviors

decreases

Feeding chow that contains 5-HTP slow release (5-HTP SR) to TPH2-R439H mice restores levels of 5-HT in the central nervous system and reduces depressive-like behaviors.

PMID:31071306 · one of two readings recorded this

enteric neuron 5-HT content

increases

Administration of 5-HTP SR to adult TPH2-R439H mice restored 5-HT to enteric neurons and reversed these abnormalities.

PMID:31071306 · one of two readings recorded this

total gastrointestinal transit and colonic motility in TPH2-R439H mice

increases

Not recorded as a finding: no outcome node matching rodent GI transit/colonic motility measures

Adult TPH2-R439H mice given oral 5-HTP SR had normalized numbers of enteric neurons, total GI transit, and colonic motility.

PMID:31071306 · one of two readings recorded this

total gastrointestinal transit and colonic motility

increases

Adult TPH2-R439H mice given oral 5-HTP SR had normalized numbers of enteric neurons, total GI transit, and colonic motility.

PMID:31071306 · one of two readings recorded this

total gastrointestinal transit and propulsive colorectal motility

increases

Adult TPH2-R439H mice given oral 5-HTP SR had normalized numbers of enteric neurons, total GI transit, and colonic motility.

PMID:31071306 · one of two readings recorded this

total gastrointestinal transit, gastric emptying, small intestinal transit and colonic motility (colonic migrating motor complexes) in a TPH2-R439H mouse model of depression

increases

Not recorded as a finding: this platform holds no node for the endpoint

Administration of 5-HTP SR to adult TPH2-R439H mice restored 5-HT to enteric neurons and reversed these abnormalities.

PMID:31071306 · one of two readings recorded this

plasma 5-hydroxytryptophan concentration (two-compartment pharmacokinetic model: half-life, Vc, clearance)

half-life about 6 hours; Vc 0.336 L/kg +/- 0.059 S.D.; plasma clearance 0.105 L/hr/kg +/- 0.015 S.D., n = 5

The biological half-life of 5-hydroxytryptophan under the experimental conditions was thus about 6 hours.

PMID:311987 · one of two readings recorded this

plasma 5-hydroxytryptophan pharmacokinetics (bi-exponential disposition, half-life, Vc, clearance)

biological half-life about 6 hours; Vc 0.336 l/kg +/- 0.059 S.D.; plasma clearance 0.105 l/hr/kg +/- 0.015 S.D.; alpha 1.433 hr-1, beta 0.113 hr-1, n = 5

The biological half-life of 5-hydroxytryptophan under the experimental conditions was thus about 6 hours.

PMID:311987 · one of two readings recorded this

plasma 5-hydroxytryptophan pharmacokinetics (biological half-life, apparent volume of the central compartment, plasma clearance) after intravenous administration

biological half-life of 5-hydroxytryptophan was about 6 hours, n = 5

Not recorded as a finding: this platform holds no node for the endpoint

The biological half-life of 5-hydroxytryptophan under the experimental conditions was thus about 6 hours.

PMID:311987 · one of two readings recorded this

predicted vs measured plasma concentration during continuous infusion

no effect, measured plasma concentrations deviated by less than 10 percent from predicted values

Measured plasma concentrations of 5-hydroxytryptophan during infusion deviated by less than 10 per cent from the predicted values.

PMID:311987 · one of two readings recorded this

tolerability of continuous intravenous 5-hydroxytryptophan infusion

infusions stopped in 4 of the experiments due to nausea and vomiting after total doses of 36-128 mg, n = 4

However, the infusions had to be stopped in four of the experiments because the patients became nauseated and vomited after total doses of only 36--128 mg.

PMID:311987 · one of two readings recorded this

tolerability of continuous intravenous infusion (nausea, vomiting)

increases, infusions stopped in four of the experiments after total doses of 36-128 mg due to nausea and vomiting

However, the infusions had to be stopped in four of the experiments because the patients became nauseated and vomited after total doses of only 36--128 mg.

PMID:311987 · one of two readings recorded this

Depression remission rate

decreases

a depression remission rate of 0.65 (95% confidence interval [CI], 0.55-0.78; remission rate [k] = 13)

PMID:31504850 · one of two readings recorded this

Depression questionnaire scores (pooled)

decreases

a large Hedges' g (1.11; 95%CI, 0.53-1.69)

PMID:31504850 · one of two readings recorded this

depression remission rate and questionnaire Hedges' g, pooled across 13/7 studies

increases, 0.65 (95% CI, 0.55-0.78)

Not recorded as a finding: the comparison was against another active treatment

Analyses revealed a depression remission rate of 0.65 (95% confidence interval [CI], 0.55-0.78; remission rate [k] = 13), and this was confirmed by the questionnaire results, which revealed a large Hedges' g (1.11; 95%CI, 0.53-1.69).

PMID:31504850 · one of two readings recorded this

depression remission rate, pooled across questionnaires in depressed patients

pooled remission rate 0.65 (95% CI 0.55-0.78); Hedges' g 1.11 (95%CI 0.53-1.69)

Not recorded as a finding: the direction is carried only as a signed number

Analyses revealed a depression remission rate of 0.65 (95% confidence interval [CI], 0.55-0.78; remission rate [k] = 13), and this was confirmed by the questionnaire results, which revealed a large Hedges' g (1.11; 95%CI, 0.53-1.69).

PMID:31504850 · one of two readings recorded this

depression remission rate, pooled proportion across 5-hydroxytryptophan studies; questionnaire depression scores as Hedges' g (scale not named)

pooled remission rate 0.65 (95% CI 0.55-0.78); Hedges' g 1.11 (95% CI 0.53-1.69)

Not recorded as a finding: the direction is carried only as a signed number

Analyses revealed a depression remission rate of 0.65 (95% confidence interval [CI], 0.55-0.78; remission rate [k] = 13), and this was confirmed by the questionnaire results, which revealed a large Hedges' g (1.11; 95%CI, 0.53-1.69).

PMID:31504850 · one of two readings recorded this

depression remission rate (pooled proportion)

increases, 0.65 (95% CI, 0.55-0.78)

Analyses revealed a depression remission rate of 0.65 (95% confidence interval [CI], 0.55-0.78; remission rate [k] = 13), and this was confirmed by the questionnaire results, which revealed a large Hedges' g (1.11; 95%CI, 0.53-1.69).

PMID:31504850 · one of two readings recorded this

Apathy Scale (AS) score

no effect

No effect of 5-HTP was seen on apathy symptoms assessed by the AS.

PMID:32067288 · one of two readings recorded this

apathy symptoms, Apathy Scale (AS)

no effect

Not recorded as a finding: no matching outcome node for the Apathy Scale

No effect of 5-HTP was seen on apathy symptoms assessed by the AS.

PMID:32067288 · one of two readings recorded this

Hamilton Depression Rating Scale (HDRS) score

decreases

Repeated-measures analysis revealed a significant improvement of depressive symptoms during the 50-mg 5-HTP treatment compared with placebo as assessed by the HDRS.

PMID:32067288 · one of two readings recorded this

serum 5-HTP pharmacokinetics

unclear, CL/F 20.40 L/h

The typical value for clearance was 20.40 L h-1 and showed inter-study variability.

PMID:32168433 · one of two readings recorded this

serum and saliva cortisol response and PK/PD modeling of a 5-HTP challenge test

Not recorded as a finding: the intervention held more than the compound

The combination of 5‐HTP (200 mg), CBD (100 mg + 50 mg), and granisetron (2 mg) was orally administrated.

PMID:32168433 · one of two readings recorded this

serum and saliva cortisol response to the 5-HTP challenge

increases, slope 4.16 ng mL-1 h

A linear approximation model was applied to fit the 5‐HTP PD effect on cortisol data with a slope of 4.16 ng mL-1 h.

PMID:32168433 · one of two readings recorded this

Y-BOCS partial and complete treatment response rate

increases

5-Hydroxytryptophan augmentation therapy demonstrated higher partial and complete treatment response rate (P = 0.032 and P = 0.001, respectively) according to the Y-BOCS total scores.

PMID:32541380 · one of two readings recorded this

Y-BOCS total and obsession/compulsion subscale scores; partial and complete treatment response rate by Y-BOCS criteria

increases

Not recorded as a finding: this platform holds no node for the endpoint

5-Hydroxytryptophan augmentation therapy demonstrated higher partial and complete treatment response rate (P = 0.032 and P = 0.001, respectively) according to the Y-BOCS total scores.

PMID:32541380 · one of two readings recorded this

All rating scales

decreases

Clomipramine has shown to be effective in that it induced significant improvement on all rating scales as compared to placebo

PMID:3312397 · one of two readings recorded this

anxiety symptomatology on the 90-item symptoms checklist (SCL-90) and the Spielberger State-Trait Anxiety Inventory State Scale

decreases, moderate reduction of symptomatology

Not recorded as a finding: this platform holds no node for the endpoint

5-HTP showed a moderate reduction of the symptomatology on the 90-item symptoms checklist (SCL-90) and the State Scale of the Spielberger State-Trait Anxiety Inventory.

PMID:3312397 · one of two readings recorded this

anxiety symptoms on the 90-item symptoms checklist (SCL-90) and the State Scale of the Spielberger State-Trait Anxiety Inventory, 5-HTP versus placebo

decreases, moderate reduction of symptomatology, n = 45

Not recorded as a finding: this platform holds no node for the endpoint

5-HTP showed a moderate reduction of the symptomatology on the 90-item symptoms checklist (SCL-90) and the State Scale of the Spielberger State-Trait Anxiety Inventory.

PMID:3312397 · one of two readings recorded this

Associated depressive symptomatology

no effect

Clomipramine and 5-HTP differed in their efficacy in that 5-HTP did not affect the associated depressive symptomatology

PMID:3312397 · one of two readings recorded this

State anxiety

decreases

5-HTP showed a moderate reduction of the symptomatology on the 90-item symptoms checklist (SCL-90) and the State Scale of the Spielberger State-Trait Anxiety Inventory

PMID:3312397 · one of two readings recorded this

Symptomatology

decreases

5-HTP showed a moderate reduction of the symptomatology on the 90-item symptoms checklist (SCL-90) and the State Scale of the Spielberger State-Trait Anxiety Inventory

PMID:3312397 · one of two readings recorded this

fibromyalgia clinical symptom severity in primary FM syndrome patients

increases, n = 50

The treatment with 5-HTP significantly improved all the clinical parameters studied in 50 patients with primary FM syndrome, with only mild and transient side effects reported.

PMID:33375373 · one of two readings recorded this

number of days with migraine headache

decreases

In another study, two weeks after treatment with 5-HTP, a significant decrease in the number of days with headache was observed.

PMID:33375373 · one of two readings recorded this

panic attack frequency and subjective anxiety in panic disorder patients

decreases

Nevertheless, in panic disorder patients, 5-HTP significantly reduced the reaction to the panic challenge, regarding number of panic attacks, panic symptom score, and subjective anxiety, when compared to placebo.

PMID:33375373 · one of two readings recorded this

plasma prolactin concentration

increases

Oral administration of 5-HTP significantly increases plasma human prolactin, suggesting that the serotonergic mechanism is involved in the regulation of prolactin secretion in humans.

PMID:33375373 · one of two readings recorded this

correlation of pancreas 11C-5-HTP uptake with HbA1c

The pancreas uptake of 11C-5-HTP correlated with the long-term metabolic control as estimated by HbA1c (P < 0.05).

PMID:33479059 · one of two readings recorded this

endocrine pancreas volume (11C-5-HTP PET uptake)

no effect, n = 16

Pancreas uptake of 11C-5-HTP (e.g., the volume of the endocrine pancreas) did not decrease from T1D diagnosis (0.23 ± 0.10 % of injected dose) to 24-month follow-up, 0.21 ± 0.14% of injected dose, and exhibited low interindividual changes.

PMID:33479059 · one of two readings recorded this

endocrine pancreas volume by 11C-5-HTP PET/MRI uptake, tracked longitudinally over 24 months after type 1 diabetes diagnosis

no effect, n = 16

Not recorded as a finding: the compound was a reagent, not an exposure

Pancreas uptake of 11C-5-HTP (e.g., the volume of the endocrine pancreas) did not decrease from T1D diagnosis (0.23 ± 0.10 % of injected dose) to 24-month follow-up, 0.21 ± 0.14% of injected dose, and exhibited low interindividual changes.

PMID:33479059 · one of two readings recorded this

pancreas 11C-5-HTP uptake (percent injected dose), as endocrine pancreas volume

no effect, n = 16

Pancreas uptake of 11C-5-HTP (e.g., the volume of the endocrine pancreas) did not decrease from T1D diagnosis (0.23 ± 0.10 % of injected dose) to 24-month follow-up, 0.21 ± 0.14% of injected dose, and exhibited low interindividual changes.

PMID:33479059 · one of two readings recorded this

pancreas perfusion

no effect, n = 16

Pancreas perfusion was unchanged from diagnosis to 24-month follow-up.

PMID:33479059 · one of two readings recorded this

pancreas volume by MRI

decreases, n = 16

Pancreas volume has a tendency to decrease from 50.2 ± 10.3 mL at T1D debut to 42.2 ± 14.6 mL after 24 months (P < 0.098).

PMID:33479059 · one of two readings recorded this

pancreatic endocrine volume via 11C-5-hydroxytryptophan PET tracer uptake (percent injected dose), longitudinally over 24 months after type 1 diabetes diagnosis

no effect, n = 16

Not recorded as a finding: the compound was a reagent, not an exposure

Pancreas uptake of 11C-5-HTP (e.g., the volume of the endocrine pancreas) did not decrease from T1D diagnosis (0.23 ± 0.10 % of injected dose) to 24-month follow-up, 0.21 ± 0.14% of injected dose, and exhibited low interindividual changes.

PMID:33479059 · one of two readings recorded this

fat mass (kg)

decreases, significant difference in change scores between groups, p = 0.048

Moreover, changes in fat mass were significantly different between the 5-HTP and placebo group (p = 0.048).

PMID:35583055 · one of two readings recorded this

lean body mass, total body water, percent body fat

no effect

Lean body mass, total body water, and % body fat did not change significantly in either group.

PMID:35583055 · one of two readings recorded this

antitumor effect / tumor growth in syngeneic mouse tumor models

decreases

In syngeneic mouse tumor models, treatment with 100 mg/kg L-5-HTP (intraperitoneal) inhibited PD-L1 expression and exhibited antitumor effect.

PMID:35728870 · one of two readings recorded this

antitumor effect / tumour growth in syngeneic mouse tumour models

decreases

Not recorded as a finding: no outcome node - mouse tumour-growth antitumor effect does not match tumour-response-rate, which requires clinical WHO/RECIST imaging criteria in patients

In syngeneic mouse tumor models, treatment with 100 mg/kg L-5-HTP (intraperitoneal) inhibited PD-L1 expression and exhibited antitumor effect.

PMID:35728870 · one of two readings recorded this

combined antitumor effect with PD-1 antibody

increases

Furthermore, L-5-HTP acted synergistically with PD-1 antibody to improve anticancer effect.

PMID:35728870 · one of two readings recorded this

granzyme B+ CD8+ activated cytotoxic T cell ratio

increases

L-5-HTP upregulated the ratio of granzyme B+ CD8+ activated cytotoxic T cells.

PMID:35728870 · one of two readings recorded this

PD-L1 surface expression (IFN-γ-induced) in tumor cells

decreases

L-5-HTP was found to suppress PD-L1 expression induced by interferon gamma (IFN-γ).

PMID:35728870 · one of two readings recorded this

PD-L1 surface expression (IFN-γ-induced)

decreases

L-5-hydroxytryptophan (L-5-HTP) was found to suppress PD-L1 expression induced by interferon gamma (IFN-γ).

PMID:35728870 · one of two readings recorded this

tumor growth / antitumor effect in syngeneic mouse models

decreases

In syngeneic mouse tumor models, treatment with 100 mg/kg L-5-HTP (intraperitoneal) inhibited PD-L1 expression and exhibited antitumor effect.

PMID:35728870 · one of two readings recorded this

bilateral hippocampal restricted diffusion (ischaemia) and antegrade/retrograde amnesia by MRI following accidental 5-HTP overdose

decreases, n = 1

Not recorded as a finding: this platform holds no node for the endpoint

Short and long-term memory improved sufficiently to return to work after two months.

PMID:35878559 · one of two readings recorded this

hippocampal diffusion MRI findings

n = 1

Magnetic resonance imaging (MRI) of the brain on day two revealed extensive symmetrical restricted diffusion bilaterally in the hippocampi, suggestive of ischaemia or seizure.

PMID:35878559 · one of two readings recorded this

hippocampal diffusion restriction on MRI and amnesia/confusion

decreases, n = 1

Short and long-term memory improved sufficiently to return to work after two months.

PMID:35878559 · one of two readings recorded this

hippocampal ischaemia on diffusion-weighted MRI and neurological/memory status following an accidental 5-HTP overdose

increases

Not recorded as a finding: this platform holds no node for the endpoint

Short and long-term memory improved sufficiently to return to work after two months.

PMID:35878559 · one of two readings recorded this

memory recovery over follow-up

increases, n = 1

Short and long-term memory improved sufficiently to return to work after two months.

PMID:35878559 · one of two readings recorded this

neurological status (amnesia, disorientation, confusion) following 5-HTP overdose

decreases, n = 1

After four hours he developed marked antegrade and retrograde amnesia, disorientation and confusion in the absence of loss of consciousness, seizure activity or features of serotonin toxicity.

PMID:35878559 · one of two readings recorded this

proportion of patients reaching a ≥20% reduction in fatigue VAS (fVAS), the trial's primary endpoint

no effect, 37.6% vs 35.6%, p = 0.83

Not recorded as a finding: no matching outcome node for a fVAS responder-proportion endpoint

The proportion of patients reaching ≥20% reduction in fVAS was similar in placebo- (37.6%) and 5-hydroxytryptophan (35.6%)-treated patients (P = .830).

PMID:35940251 · one of two readings recorded this

proportion reaching ≥20% reduction in fatigue VAS (fVAS), primary endpoint

no effect, 37.6% vs 35.6%, p = 0.83

The proportion of patients reaching ≥20% reduction in fVAS was similar in placebo- (37.6%) and 5-hydroxytryptophan (35.6%)-treated patients (P = .830).

PMID:35940251 · one of two readings recorded this

serum 5-hydroxytryptophan concentration

increases, estimated mean difference 52.66 ng/mL

During 5-hydroxytryptophan treatment, a significant increase in serum 5-hydroxytryptophan (estimated mean difference, 52.66 ng/mL; 95% confidence interval [CI], 39.34-65.98 ng/mL; P < .001) and serotonin (3.0 ng/mL; 95 CI, 1.97-4.03 ng/mL; P < .001) levels was observed compared with placebo.

PMID:35940251 · one of two readings recorded this

serum serotonin concentration

increases, 3.0 ng/mL

During 5-hydroxytryptophan treatment, a significant increase in serum 5-hydroxytryptophan (estimated mean difference, 52.66 ng/mL; 95% confidence interval [CI], 39.34-65.98 ng/mL; P < .001) and serotonin (3.0 ng/mL; 95 CI, 1.97-4.03 ng/mL; P < .001) levels was observed compared with placebo.

PMID:35940251 · one of two readings recorded this

regioselective hydroxylation of the tryptophan indole ring to hydroxytryptophan

increases

These enzymes utilize a histidine-ligated heme cofactor and molecular oxygen or hydrogen peroxide to catalyze regioselective hydroxylation on the tryptophan indole moiety, which is mechanistically distinct from their animal counterparts from the nonheme iron enzyme family.

PMID:37653171 · one of two readings recorded this

serial blood and urine 5-hydroxytryptophan and serotonin concentrations during haemodialysis treatment for 5-HTP toxicity in a dog

decreases

Not recorded as a finding: this platform holds no node for the endpoint

Clinical signs resolved completely within 12 h.

PMID:37659074 · one of two readings recorded this

serotonin syndrome clinical signs (altered mentation, ataxia) and time to resolution

decreases, n = 1

Clinical signs resolved completely within 12 h.

PMID:37659074 · one of two readings recorded this

serotonin syndrome clinical signs and haemodialysis clearance of 5-HTP/serotonin

decreases, n = 1

Clinical signs resolved completely within 12 h.

PMID:37659074 · one of two readings recorded this

plasma serotonin concentration during syncope

increases, p = 0.037

Notably, plasma serotonin levels significantly increased during syncope in patients with drug-free VVS (P=.037), and a greater change in serotonin correlated with a shorter time to syncope (R2=0.38; P=.015).

PMID:39313082 · one of two readings recorded this

plasma serotonin levels during syncope in drug-free VVS patients

increases, p = 0.037

Notably, plasma serotonin levels significantly increased during syncope in patients with drug-free VVS (P=.037), and a greater change in serotonin correlated with a shorter time to syncope (R2=0.38; P=.015).

PMID:39313082 · one of two readings recorded this

endogenous plasma 5-hydroxytryptophan, 5-HT and 5-HIAA by ELISA in postmenopausal women with osteoporosis versus normal BMD

increases, plasma 5-HTP, 5-HT and 5-HIAA elevated in postmenopausal osteoporosis patients, n = 287

Not recorded as a finding: the compound is what was measured, not what was given

Plasma levels of 5-hydroxytryptophan (5-HTP), 5-HT, and 5-hydroxyindoleacetic acid (5-HIAA) were elevated in PMOP patients and showed correlations with bone turnover markers and BMD.

PMID:40530681 · one of two readings recorded this

Plasma 5-HT precursors and metabolites levels

increases

Elevated levels were particularly pronounced in women with ≥ 12 years since menopause (YSM), and were associated with a higher risk of developing PMOP

PMID:40530681 · one of two readings recorded this

Plasma 5-HTP, 5-HT and 5-HIAA levels

increases, n = 287

Plasma levels of 5-hydroxytryptophan (5-HTP), 5-HT, and 5-hydroxyindoleacetic acid (5-HIAA) were elevated in PMOP patients and showed correlations with bone turnover markers and BMD

PMID:40530681 · one of two readings recorded this

plasma 5-hydroxytryptophan level by ELISA in postmenopausal women by osteoporosis status

increases, elevated in PMOP patients, correlated with bone turnover markers and BMD

Not recorded as a finding: the compound is what was measured, not what was given

Plasma levels of 5-hydroxytryptophan (5-HTP), 5-HT, and 5-hydroxyindoleacetic acid (5-HIAA) were elevated in PMOP patients and showed correlations with bone turnover markers and BMD.

PMID:40530681 · one of two readings recorded this

Predictive value for PMOP of combined 5-HTP, 5-HT and 5-HIAA

increases

Combined analysis of the three biomarkers demonstrated greater predictive value than individual markers

PMID:40530681 · one of two readings recorded this

plasma amyloid beta 40 and 42, GABA

no effect

However, no effects were observed in the levels of plasma Aβ40, Aβ42, and GABA, or in the Aβ42/Aβ40 ratio.

PMID:40944161 · one of two readings recorded this

5-HTP secretion by enterochromaffin cells

increases

Combined with the results of cell experiments, it is shown that KXS can increase the secretion of 5-hydroxytryptophan (5-HTP) by EC cells.

PMID:41161620 · one of two readings recorded this

5-hydroxytryptophan (5-HTP) secretion by enterochromaffin cells, quantified by UPLC-TQ-MS/MS, in a chronic-unpredictable-mild-stress rat model treated with Kai-Xin-San

increases

Not recorded as a finding: the compound is what was measured, not what was given

KXS can increase the secretion of 5-hydroxytryptophan (5-HTP) by EC cells.

PMID:41161620 · one of two readings recorded this

5-hydroxytryptophan (5-HTP) secretion by enterochromaffin cells

increases

KXS can increase the secretion of 5-hydroxytryptophan (5-HTP) by EC cells.

PMID:41161620 · one of two readings recorded this

5-hydroxytryptophan secretion by enterochromaffin cells as part of the tryptophan-5-HTP-5-HT pathway in a CUMS rat depression model

increases

Not recorded as a finding: the compound is what was measured, not what was given

Combined with the results of cell experiments, it is shown that KXS can increase the secretion of 5-hydroxytryptophan (5-HTP) by EC cells.

PMID:41161620 · one of two readings recorded this

depressive symptoms via tryptophan-5-HTP-5-HT pathway

decreases

KXS may exert antidepressant effects by regulating the Trp -5-HTP-5-HT metabolic pathway in the body.

PMID:41161620 · one of two readings recorded this

hypothalamic-pituitary-adrenal axis hyperfunction and hippocampal brain-derived neurotrophic factor expression

decreases

Pharmacological results showed that KXS significantly improved hyperfunction of the hypothalamic-pituitary-adrenal axis, improved damage of intestinal barrier and increased the expression of brain-derived neurotrophic factor in hippocampus.

PMID:41161620 · one of two readings recorded this

hypothalamic-pituitary-adrenal axis hyperfunction and intestinal barrier damage

decreases

Pharmacological results showed that KXS significantly improved hyperfunction of the hypothalamic-pituitary-adrenal axis, improved damage of intestinal barrier and increased the expression of brain-derived neurotrophic factor in hippocampus.

PMID:41161620 · one of two readings recorded this

5-HTP consumption and TMAO production by gut bacteria

decreases

This intervention restored metabolic balance by reducing 5-HTP consumption and TMAO production and increasing butyrate levels.

PMID:41499937 · one of two readings recorded this

5-hydroxytryptophan (5-HTP) consumption and trimethylamine N-oxide (TMAO) production

decreases

This intervention restored metabolic balance by reducing 5-HTP consumption and TMAO production and increasing butyrate levels.

PMID:41499937 · one of two readings recorded this

Escherichia fergusonii growth / bacterial abundance

decreases

The F.l-HP combination therapy significantly suppressed the growth of E. fergusonii while promoting the proliferation of beneficial probiotics.

PMID:41499937 · one of two readings recorded this

gut bacterial 5-HTP consumption and TMAO production by Escherichia fergusonii in a Parkinson's disease enterotype model

decreases

Not recorded as a finding: the compound is what was measured, not what was given

This intervention restored metabolic balance by reducing 5-HTP consumption and TMAO production and increasing butyrate levels.

PMID:41499937 · one of two readings recorded this

intestinal barrier integrity (zonula occludens-1 expression) in Caco-2 cells

increases

In intestinal cells, it enhanced gut barrier integrity by upregulating zonula occludens-1 expression and activating p-AMPKα signaling.

PMID:41499937 · one of two readings recorded this

neuroinflammation and oxidative stress in neuronal cells

decreases

Consequently, F.l-HP treatment alleviated neuroinflammation and oxidative stress in neuronal cells, restoring mitochondrial function via the p-Akt pathway.

PMID:41499937 · one of two readings recorded this

neuroinflammation and oxidative stress in PC12 neuronal cells

decreases

Consequently, F.l-HP treatment alleviated neuroinflammation and oxidative stress in neuronal cells, restoring mitochondrial function via the p-Akt pathway.

PMID:41499937 · one of two readings recorded this

thermal aggregation onset temperature and conformational stability of gammaS-crystallin with 5-hydroxytryptophan site-specifically incorporated at residue 163, versus wild-type, by biophysical assays and simulations

decreases

Not recorded as a finding: the compound was a reagent, not an exposure

Although the overall fold and stability of the two proteins were comparable, the aggregation of γS-W163(5HTP) was triggered at notably lower temperatures compared to γS-WT.

PMID:41548873 · one of two readings recorded this

thermal aggregation onset temperature of gammaS-crystallin

decreases

Although the overall fold and stability of the two proteins were comparable, the aggregation of γS-W163(5HTP) was triggered at notably lower temperatures compared to γS-WT.

PMID:41548873 · one of two readings recorded this

thermal aggregation temperature of γS-crystallin protein with 5-hydroxytryptophan substituted at residue 163 (oxidation mimic)

decreases

Not recorded as a finding: the compound was a reagent, not an exposure

the aggregation of γS-W163(5HTP) was triggered at notably lower temperatures compared to γS-WT.

PMID:41548873 · one of two readings recorded this

thermal aggregation temperature of γS-crystallin

decreases

the aggregation of γS-W163(5HTP) was triggered at notably lower temperatures compared to γS-WT.

PMID:41548873 · one of two readings recorded this

adverse events (fatigue, nausea, vomiting)

increases, n = 112

All adverse event reports were from participants on the 5-HTP intervention, and all participants who reported nausea or vomiting were female.

PMID:42160304 · one of two readings recorded this

distractibility on the Eriksen flanker task and an N-back task with auditory distractors (reaction time, accuracy, standard deviation of reaction time, false positives)

no effect

Not recorded as a finding: no matching outcome node for flanker/N-back interference-control performance

No other differences were noted because of 5-HTP administration, and there was no significant interaction related to ADHD trait groups.

PMID:42160304 · one of two readings recorded this

flanker task reaction time, accuracy, standard deviation of reaction time

no effect

No other differences were noted because of 5-HTP administration, and there was no significant interaction related to ADHD trait groups.

PMID:42160304 · one of two readings recorded this

N-back task silent-trial accuracy

decreases, placebo 53.25% to 60.82%; 5-HTP 54.08% to 53.69%

Placebo saw an increase in mean from 53.25% to 60.82% of silent targets hit, whereas 5-hydroxytryptophan administration had an initial mean of 54.08%, which was reduced to 53.69% post-administration.

PMID:42160304 · one of two readings recorded this

paradoxical (REM) sleep time and percentage, and slow-wave sleep (SWS) amount, tracked across repeated high-dose treatment

decreases, paradoxical sleep time and percentage tend to show a decrease during the 2nd week of treatment, followed by a rebound effect after the end of treatment, n = 3

Not recorded as a finding: this platform holds no node for the endpoint

The paradoxical sleep time and percentage tend to show a decrease during the 2nd week of treatment, followed by a rebound effect after the end of the treatment.

PMID:60227 · one of two readings recorded this

paradoxical (REM) sleep time and percentage; slow-wave sleep (SWS) amount

decreases, decrease during the 2nd week of treatment, followed by a rebound effect after the end of treatment, n = 3

Not recorded as a finding: this platform holds no node for the endpoint

The paradoxical sleep time and percentage tend to show a decrease during the 2nd week of treatment, followed by a rebound effect after the end of the treatment.

PMID:60227 · one of two readings recorded this

paradoxical (REM) sleep time and percentage

decreases, decrease during the 2nd week of treatment, followed by a rebound effect after the end of treatment, n = 3

The paradoxical sleep time and percentage tend to show a decrease during the 2nd week of treatment, followed by a rebound effect after the end of the treatment.

PMID:60227 · both readings recorded this

paradoxical sleep and SWS response to 5-HTP combined with benserazide

unclear, similar results were obtained after administration of 5-HTP together with RO.04.4602

Similar results were obtained after administration of 5-HTP together with RO.04.4602.

PMID:60227 · one of two readings recorded this

slow wave sleep (SWS) amount

increases, increase in SWS that persisted after the end of treatment, in two subjects with initially low SWS, n = 2

In two subjects who initially had a small amount of slow wave sleep (SWS), the treatment induced an increase in SWS that persisted after the end of the treatment.

PMID:60227 · both readings recorded this

5-HTP oral bioavailability in combination with carbidopa

48% +/- 15%

The bioavailability of 5-HTP after oral administration in combination with carbidopa was calculated as 48% +/- 15 (mean +/- SD).

PMID:6187038 · one of two readings recorded this

5-HTP plasma half-life and clearance

n = 5

The biological half-life of 5-HTP ranged from 2.2 to 7.4 hours, and the plasma clearance ranged from 0.10 to 0.23 1/kg/hour.

PMID:6187038 · both readings recorded this

extent of absorption of 5-HTP and AUC of 5-hydroxyindoleacetic acid with carbidopa pretreatment

increases, n = 8

Pretreatment with carbidopa caused a significant increase in the extent of absorption of unchanged 5-HTP, and a significant reduction in the area under the plasma concentration-time curves of 5-hydroxyindoleacetic acid.

PMID:6187038 · one of two readings recorded this

extent of absorption of unchanged 5-HTP and AUC of 5-hydroxyindoleacetic acid, with vs without carbidopa pretreatment

increases, n = 8

Pretreatment with carbidopa caused a significant increase in the extent of absorption of unchanged 5-HTP, and a significant reduction in the area under the plasma concentration-time curves of 5-hydroxyindoleacetic acid.

PMID:6187038 · one of two readings recorded this

gastrointestinal side effects related to plasma 5-HTP concentration

Gastrointestinal side effects appeared to be related to the 5-HTP plasma concentration.

PMID:6187038 · one of two readings recorded this

oral bioavailability of 5-HTP with carbidopa

48% +/- 15 (mean +/- SD)

The bioavailability of 5-HTP after oral administration in combination with carbidopa was calculated as 48% +/- 15 (mean +/- SD).

PMID:6187038 · one of two readings recorded this

blood 5-HT levels in platelet-rich plasma

no effect

This occurred without significant changes in blood 5-HT levels measured in platelet-rich plasma.

PMID:7619676 · one of two readings recorded this

Extra-renal 5-HT formation

increases, n = 5

there was greater extra-renal formation of 5-HT following 5-HTP administration than after glu-5-HTP

PMID:7690583 · one of two readings recorded this

plasma aldosterone; urinary 5-HT excretion; urinary sodium excretion after intravenous 5-HTP versus placebo

increases, 5-HTP, but not glu-5-HTP, significantly increased plasma aldosterone, n = 5

Not recorded as a finding: this platform holds no node for the endpoint

5-HTP, but not glu-5-HTP, significantly increased plasma aldosterone.

PMID:7690583 · one of two readings recorded this

plasma aldosterone; urinary 5-HT excretion; urinary sodium excretion

increases, significant increase in plasma aldosterone with 5-HTP but not glu-5-HTP

Not recorded as a finding: this platform holds no node for the endpoint

5-HTP, but not glu-5-HTP, significantly increased plasma aldosterone.

PMID:7690583 · one of two readings recorded this

Plasma aldosterone

increases, n = 5

5-HTP, but not glu-5-HTP, significantly increased plasma aldosterone

PMID:7690583 · one of two readings recorded this

Plasma aldosterone

no effect, n = 5

5-HTP, but not glu-5-HTP, significantly increased plasma aldosterone

PMID:7690583 · one of two readings recorded this

Plasma renin activity

no effect, n = 5

There was no increase in plasma renin activity with either compound

PMID:7690583 · one of two readings recorded this

Pulse rate and blood pressure

no effect, n = 5

There were no significant changes in pulse rate or blood pressure

PMID:7690583 · one of two readings recorded this

Urinary 5-HT excretion

increases, n = 5

Both compounds increased urinary excretion of 5-HT

PMID:7690583 · one of two readings recorded this

Urinary 5-HT excretion

increases, n = 5

Both compounds increased urinary excretion of 5-HT

PMID:7690583 · one of two readings recorded this

Urinary sodium excretion

no effect, n = 5

5-HTP reduced mean urinary sodium excretion but this effect was not statistically significant

PMID:7690583 · one of two readings recorded this

Urinary sodium excretion

decreases, n = 5

Glu-5-HTP was significantly antinatriuretic

PMID:7690583 · one of two readings recorded this

Cumulative urinary 5-hydroxytryptamine excretion

increases, n = 9

Cumulative urinary 5-hydroxytryptamine excretion over the 3 h observation period rose by about 370-fold after 5-hydroxy-L-tryptophan and 390-fold after gamma-L-glutamyl-5-hydroxy-L-tryptophan

PMID:8287650 · one of two readings recorded this

Cumulative urinary 5-hydroxytryptamine excretion

increases, n = 9

Cumulative urinary 5-hydroxytryptamine excretion over the 3 h observation period rose by about 370-fold after 5-hydroxy-L-tryptophan and 390-fold after gamma-L-glutamyl-5-hydroxy-L-tryptophan

PMID:8287650 · one of two readings recorded this

Effective renal plasma flow and glomerular filtration rate

no effect, n = 9

These changes occurred without significant alterations in effective renal plasma flow and glomerular filtration rate

PMID:8287650 · one of two readings recorded this

plasma aldosterone concentration, plasma renin activity, urine flow rate and urinary sodium excretion after intravenous 5-HTP versus placebo

increases, both prodrugs significantly increased plasma aldosterone without a rise in plasma renin activity, n = 9

Not recorded as a finding: this platform holds no node for the endpoint

Both 5-Hydroxy-L-tryptophan and gamma-L-glutamyl-5-hydroxy-L-tryptophan significantly increased plasma aldosterone concentration without a concomitant rise in plasma renin activity.

PMID:8287650 · one of two readings recorded this

plasma aldosterone concentration; plasma renin activity; urine flow rate; urinary sodium excretion; urinary 5-HT excretion

increases, significant increase in plasma aldosterone without a rise in plasma renin activity (both prodrugs)

Not recorded as a finding: this platform holds no node for the endpoint

Both 5-hydroxy-L-tryptophan and gamma-L-glutamyl-5-hydroxy-L-tryptophan significantly increased plasma aldosterone concentration without a concomitant rise in plasma renin activity.

PMID:8287650 · one of two readings recorded this

Plasma aldosterone concentration

increases, n = 9

Both 5-hydroxy-L-tryptophan and gamma-L-glutamyl-5-hydroxy-L-tryptophan significantly increased plasma aldosterone concentration without a concomitant rise in plasma renin activity

PMID:8287650 · one of two readings recorded this

Plasma renin activity

no effect, n = 9

Both 5-hydroxy-L-tryptophan and gamma-L-glutamyl-5-hydroxy-L-tryptophan significantly increased plasma aldosterone concentration without a concomitant rise in plasma renin activity

PMID:8287650 · one of two readings recorded this

Urinary 5-hydroxy-L-tryptophan excretion

increases, n = 9

Urinary 5-hydroxy-L-tryptophan excretion was three times higher after administration of gamma-L-glutamyl-5-hydroxy-L-tryptophan than after 5-hydroxy-L-tryptophan infusion

PMID:8287650 · one of two readings recorded this

Urinary 5-hydroxyindole-3-acetic acid excretion

increases, n = 9

Urinary 5-hydroxyindole-3-acetic acid excretion after 5-hydroxy-L-tryptophan infusion was significantly greater than that after gamma-L-glutamyl-5-hydroxy-L-tryptophan administration

PMID:8287650 · one of two readings recorded this

Urinary dopamine excretion

no effect, n = 9

Urinary dopamine excretion was not affected by either compound when compared with placebo

PMID:8287650 · one of two readings recorded this

Urinary sodium excretion

decreases, n = 9

gamma-L-Glutamyl-5-hydroxy-L-tryptophan was antinatriuretic but did not affect urine output

PMID:8287650 · one of two readings recorded this

Urine flow rate and urinary sodium excretion

decreases, n = 9

5-Hydroxy-L-tryptophan significantly reduced urine flow rate and urinary sodium excretion

PMID:8287650 · one of two readings recorded this

Urine output

no effect, n = 9

gamma-L-Glutamyl-5-hydroxy-L-tryptophan was antinatriuretic but did not affect urine output

PMID:8287650 · one of two readings recorded this

Cough response to capsaicin

no effect, n = 8

whereas neither infusion reduced responses to capsaicin

PMID:8444719 · one of two readings recorded this

Cough response to chloride-deficient solution

decreases, p = 0.035, n = 8

Both 5-HT and 5-HTP reduced cough responses to the chloride-deficient solution (P = 0.035 and P = 0.017, respectively) with respect to saline control

PMID:8444719 · one of two readings recorded this

Cough response to chloride-deficient solution

decreases, p = 0.017, n = 8

Both 5-HT and 5-HTP reduced cough responses to the chloride-deficient solution (P = 0.035 and P = 0.017, respectively) with respect to saline control

PMID:8444719 · one of two readings recorded this

cough response to inhaled chloride-deficient solution and to capsaicin challenge

decreases, 5-HTP reduced cough responses to chloride-deficient solution (P = 0.017) versus saline; no reduction for capsaicin

Not recorded as a finding: this platform holds no node for the endpoint

Both 5-HT and 5-HTP reduced cough responses to the chloride-deficient solution (P = 0.035 and P = 0.017, respectively) with respect to saline control, whereas neither infusion reduced responses to capsaicin.

PMID:8444719 · one of two readings recorded this

cough response to inhaled chloride-deficient solution and to capsaicin during infusion of 5-HTP versus saline

decreases, both 5-HT and 5-HTP reduced cough responses to the chloride-deficient solution; neither reduced responses to capsaicin, n = 8

Not recorded as a finding: this platform holds no node for the endpoint

Both 5-HT and 5-HTP reduced cough responses to the chloride-deficient solution (P = 0.035 and P = 0.017, respectively) with respect to saline control, whereas neither infusion reduced responses to capsaicin.

PMID:8444719 · one of two readings recorded this

Heart rate

increases, p = 0.01, n = 8

5-HT caused a transient increase in heart rate that was not observed with a similar dose of 5-HTP or saline (P < 0.01)

PMID:8444719 · one of two readings recorded this

Heart rate

no effect, n = 8

5-HT caused a transient increase in heart rate that was not observed with a similar dose of 5-HTP or saline (P < 0.01)

PMID:8444719 · one of two readings recorded this

Respiratory rate and blood pressure

no effect, n = 8

Respiratory rate and blood pressure were not affected by experimental infusions but rose during cough challenge

PMID:8444719 · one of two readings recorded this

clinical effectiveness of 5-HTP in depression, fibromyalgia, binge eating associated with obesity, chronic headaches, and insomnia

increases

Therapeutic administration of 5-HTP has been shown to be effective in treating a wide variety of conditions, including depression, fibromyalgia, binge eating associated with obesity, chronic headaches, and insomnia.

PMID:9727088 · one of two readings recorded this

fraction of an oral 5-HTP dose reaching the bloodstream

increases, about 70 percent

5-HTP is well absorbed from an oral dose, with about 70 percent ending up in the bloodstream.

PMID:9727088 · one of two readings recorded this

symptoms of depression, anxiety, insomnia and somatic pain in fibromyalgia patients

increases

Serotonin substrate supplementation, via L-tryptophan or 5-hydroxytryptophan (5-HTP), has been shown to improve symptoms of depression, anxiety, insomnia and somatic pains in a variety of patient cohorts.

PMID:9802912 · one of two readings recorded this